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Abstract
Chromogranin A is a member of the granin glycoprotein family that is expressed by the endocrine and neuroendocrine cells of different 
organs. Intracellularly, chromogranin A contributes to the regulation of secretion and gives several cleavage products after secretion. 
Some of its cleavage products modify the hormone functions in autocrine and paracrine ways, while the functions of others have not 
been fully understood yet.
Serum chromogranin A level is most prominently used in neuroendocrine tumour diagnostics. In addition, recent studies have suggested 
that chromogranin A and some of its cleavage products (pancreastatin and WE-14) also play important roles in the pathogenesis of the 
various forms of diabetes mellitus, but their exact mechanisms still need to be clarified.
Higher chromogranin A, pancreastatin, and WE-14 levels have been reported in type 1, type 2, and gestational diabetic patients compared 
to healthy controls. A notable connection has been inferred through the observation that type 1 diabetes mellitus is not at all or rarely 
developed in chromogranin A gene-knockout, non-obese diabetic model mice compared to non-knockout, non-obese diabetic mice. 
Pancreastatin inhibits insulin release in various cell and animal models, and WE-14 serves as an autoantigen for both CD4+ and CD8+ 
beta cell-destructive diabetogenic T-cell clones in type 1 diabetes.
Chromogranin A contributes to the pathogenesis of diabetes mellitus according to the available literature. The current findings facilitate 
further investigation to unravel the deeper relationships between this glycoprotein and diabetes. (Endokrynol Pol 2018; 69 (5): 598–610)
Key words: chromogranin A, diabetes mellitus, diabetes mellitus type 1, diabetes mellitus type 2, gestational diabetes, mice inbred NOD, 
pancreastatin, WE-14
Streszczenie
Chromogranina A jest członkiem rodziny glikoprotein granin i występuje w komórkach endokrynnych i neuroendokrynnych różnych 
organów. Chromogranina A wewnątrzkomórkowo przyczynia się do regulacji wydzielania, również tworzą się liczne produkty jej rozkła-
du po wydzielaniu. Niektóre produkty rozpadu modyfikują funkcje hormonalne w sposób autokrynny lub parakrynny, a w przypadku 
innych produktów funkcje te nie są w pełni znane.
Stężenie chromograniny A w surowicy jest używane przede wszystkim w diagnostyce guzów neuroendokrynnych. Co więcej, z ostat-
nich badań wynika, że chromogranina A oraz niektóre jej produkty rozpadu, takie jak pankreostatyna i WE-14, odgrywają istotną rolę 
w patogenezie różnych form cukrzycy, choć dokładny mechanizm pozostaje do wyjaśnienia.
Wyższe stężenie chromograniny A, pankreostatyny i WE-14 w porównaniu z grupą kontrolną było wykryte u pacjentów z cukrzycą typu 
1, 2 oraz cukrzycą ciążową. Na podstawie obserwacji wyciągnięto ważny wniosek, że cukrzyca typu 1 w ogóle nie lub bardzo rzadko 
rozwija się u nieotyłych, transgenicznych pozbawionych chromograniny A myszy z cukrzycą w porównaniu z niezmutowanymi, nie-
otyłymi myszami z cukrzycą. 
Pankreostatyna hamuje wydzielanie insuliny w różnorodnych modelach komórkowych oraz zwierzęcych, a WE-14 służy jako autoantygen 
zarówno dla klonów CD4+ i CD8+ limfocytów T niszczących komórki β w cukrzycy typu 1.
Według dostępnej literatury, chromogranina A przyczynia się do patogenezy cukrzycy. Obecne ustalenia motywują do dalszych badań, 
aby wyjaśnić bardziej ścisłe zależności między tą glikoproteiną a cukrzycą. (Endokrynol Pol 2018; 69 (5): 598–610)
Słowa kluczowe: chromogranina A, cukrzyca, cukrzyca typu 1, cukrzyca typu 2, cukrzyca ciążowa, myszy szczepu NOD, pankreostatyna, WE-14
Introduction
Diabetes mellitus is a complex metabolic disorder 
with multifactorial aetiology. It is one of the most 
prevalent diseases in our time, occurring in approxi-
mately 8–9% of the world’s population. Its current 
classification — recently described by the American 
Diabetes Association [1] — includes several forms: 
type 1 diabetes mellitus (T1DM), type 2 diabetes 
mellitus (T2DM), other specific types (for example 
genetic defect forms, endocrinopathies, diseases of 
the exocrine pancreas and drug- or chemical-induced 
Zoltan Herold, Semmelweis University 2nd Department of Internal Medicine, H-1088 Szentkiralyi u. 46, Budapest, Hungary, tel.: +36 20 
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T cell receptors, but the impact of cytotoxic CD8+ T-
cell clones through MHC class I was later confirmed 
too [14].
While T1DM has an autoimmune pathomecha-
nism, T2DM is caused by insulin resistance leading 
to elevated insulin and glucose levels in blood, but 
a subsequent beta cell dysfunction may develop at 
a later time. Genetic, epigenetic, and lifestyle factors 
— such as obesity, lack of physical activity, incorrect 
quantity and quality of food — contribute to the devel-
opment of T2DM. The genetic predisposition of T2DM 
is confirmed by both heritability estimates and twin 
studies, genome-wide association studies provided 
a large number of variants that are associated with 
a higher risk of developing T2DM, and several candi-
date genes were identified which have been proven 
to have a relationship to the disease [15]. T2DM is 
often developed from metabolic syndrome, which is 
a complex disease including obesity, dyslipidaemia, in-
sulin resistance, and hypertension [16, 17]. The clinical 
relevance of T2DM is due to its high prevalence and 
the associated cardiovascular and other complications 
(such as nephropathy, neuropathy, retinopathy) that 
can affect patients’ quality of life [5, 18, 19].
GDM is caused by insulin resistance due to the 
hormonal changes of the placenta in pregnant women, 
and is characterised by elevated blood glucose and 
slightly increased insulin levels. Environmental factors 
such as obesity and genetic factors, for example a first-
degree relative who has T2DM, are responsible for its 
development. GDM endangers both mother and foetus; 
diabetes forms), and gestational diabetes mellitus 
(GDM) (Table I) [2–8].
T1DM is caused by the autoimmune destruction 
of the insulin-producing beta cells in the pancreatic 
islets and can be characterised by the appearance of 
various autoantibodies, including islet cell-, glutamic 
acid decarboxylase-, insulin-, zinc transporter 8-, and 
islet antigen-2 autoantibodies. T1DM accounts for the 
majority of young-onset diabetes cases and shows 
family aggregation, indicating a genetic background. 
Result from the study of the Type 1 Diabetes Genetics 
Consortium showed that human leukocyte antigen 
(HLA) genes represent almost 50% of the familial risk 
for developing T1DM, from which HLA class II DR and 
DQ alleles are the most specific [9, 10]. Recent results 
suggest that some environmental factors (for example 
maternal factors, viral infections, and toxic substances) 
in genetically predisposed subjects may also play 
a role in the development of T1DM [9]. The immune-
mediated pathogenesis in T1DM features islet-specific 
autoantigens, antigen-specific beta cell-destroying 
T-cell clones, and the subsequent inflammation of 
islets. Diabetogenic T-cell clones have been identi-
fied both in humans and non-obese diabetic (NOD) 
mice, the prevailing animal model of T1DM. The early 
presence of islet autoantigens and diabetogenic T-cell 
clones prognoses the destruction of the pancreatic 
beta cells [4, 11–13]. It was thought for a long time that 
helper CD4+ T cells mediate the autoimmune destruc-
tion of the pancreatic islets through an interaction with 
Major Histocompatibility Complex (MHC) class II and 
Table I. Comparison of type 1, type 2, and gestational diabetes
Tabela I. Porównanie cukrzycy typu 1, 2 i cukrzycy ciążowej
Type 1 diabetes mellitus (T1DM) Type 2 diabetes mellitus (T2DM) Gestational diabetes mellitus 
(GDM)
Prevalence ~10% of the diabetic patients ~90% of the diabetic patients ~14% of the pregnancies
Age at recognition Usually young Usually older Second trimester of the pregnancy
Development (speed, onset) Fast, acute onset Slow, usually when a comorbidity is 
recognised
Only during routine testing
Overweight Usually no Often Often
Insulin response Insulin deficiency Insulin resistance Usually insulin resistance
Family history Usually rare Usually diabetes in family Usually T2DM in family
Pathomechanism Autoimmune destruction of the 
pancreatic beta cells
Insulin resistance and later beta cell 
dysfunction
Insulin resistance caused by 
hormonal changes of the placenta
Treatment Insulin Early diagnosis: diet and change of 
lifestyle
Late diagnosis: oral antidiabetics and/
or insulin
First: diet and exercise
If treatment targets are not met in 
1–2 weeks: insulin
Common comorbidities Various autoimmune diseases and 
mental disorders [141]
Obesity, dyslipidaemia, cardiovascular 
events and hypertension, micro- and 
macrovascular complications
Mother: Hypertension, pre-eclampsia
Foetus: shoulder dystocia, stillbirth, 
hypoglycaemia, higher birthweight
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it increases the chance of pre-eclampsia, and it may lead 
to stillbirth if untreated. In 2017, approximately 14% 
of pregnancies were affected by GDM; however, the 
prevalence can vary in different populations [19]. After 
birth, GDM is usually resolved, but the risk of develop-
ing T2DM later in life is significantly increased [3, 19, 20].
Chromogranin A (CgA) is a 439 amino acid (48kDa)- 
-long protein expressed by the endocrine and neu-
roendocrine cells of diverse organs. Several cleavage 
proteins are generated from CgA, some of which have 
well-known biological activity, while the exact function 
of others is unclear. The main intracellular function 
of CgA is to sort appropriate proteins into secretory 
granules, while cleavage products act as extracellular 
regulator molecules. Both the CgA protein and some of 
its cleavage proteins — including WE-14, pancreastatin 
and catestatin — show a relationship to carbohydrate 
metabolism and have significant involvement in dia-
betes mellitus [21–26].
CgA can be detected from serum, plasma, saliva, 
or tissue samples using different techniques (Table II). 
It is one of the most prominent secretory products of 
neuroendocrine tumours, and therefore its serum level 
is an informative marker to confirm the diagnosis and 
to monitor the effectiveness of the treatment [27–32]. 
However, recent studies indicate that its usage may be 
limited due to various factors: 1. non-CgA-producing 
neuroendocrine tumours, 2. other tumour types may 
produce CgA as well, 3. benign conditions (such as 
atrophic gastritis or renal dysfunction), and 4. antacid 
usage may also increase serum CgA levels [33]. Like 
the whole CgA molecule, WE-14 can also be detected 
in blood samples [34].
In this review, the available literature on CgA and 
its cleavage proteins is discussed, focusing mainly on 
its biochemistry, distribution, and functions, and its 
relationships to diabetes and carbohydrate metabolism.
The discovery of chromogranin A and its 
diabetes-related cleavage products
Chromogranin A (formerly parathyroid secretory pro-
tein 1 or pituitary secretory protein I) is a member of the 
granin glycoprotein family. It is built from 439 amino 
acids (48kDa) [21]. The name ‘chromogranin’ originates 
from 1967 when Blashko et. al. isolated soluble proteins 
from bovine chromaffin granules [35, 36], and the first 
identified protein was named “chromogranin A” [37].
Nearly half of the hormone peptides of mammals 
have an amide structure at their C-terminal end for bio-
logical activity. To identify peptides containing this alpha-
amide structure, an enzymatic release method, which in-
cludes thin layer chromatography, was developed. With 
this method, a large variety of peptides — often without 
knowing their exact function — were identified [38]. 
In 1986, from porcine pancreas, a 49 amino acid-long 
peptide was isolated that was able to inhibit glucose-
stimulated insulin secretion. It was named pancreastatin 
(PST). After the protein’s exact sequence was available, 
several publications appeared indicating that PST closely 
resembles some parts of bovine CgA. The relationship 
between the two proteins was confirmed in 1988, when 
the complete DNA sequence of the porcine CgA gene, 
including the full-length PST sequence, was published 
[38, 39]. This was the first evidence that hormone-like 
proteins are formed from CgA [38, 40].
Table II. The available detection methods for chromogranin A. In routine neuroendocrine tumour diagnostics, the most 
frequently used techniques for detecting chromogranin A from blood samples are RIA and ELISA [25]
Tabela II. Dostępne metody wykrywania chromograniny A. Najczęściej używane techniki detekcji chromograniny A ze krwi 
w diagnostyce rutynowej guzów neuroendokrynnych to RIA i ELISA [25]
Technique Type of samples Comment
Radioimmunoassay1, 2 (RIA) and immunoradiometric assay1, 2 (IRMA) 
[134, 135]
Serum
Plasma
Plasma concentrations are significantly higher 
[142, 143]
Used in neuroendocrine tumour diagnostics 
routinely
Enzyme-linked immunosorbent assay1, 2 (ELISA) [137, 144] Serum
Plasma
Time-Resolved Amplified Cryptate Emission (TRACE) [145, 146] Serum Currently for research only
Immunohistochemistry1, 2 [147] Tissue Used in neuroendocrine tomour diagnostics
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting (Western Blot) [136]
Saliva Currently for research only
1It is important to emphasise that, in accordance with international recommendations, for proper detection, two-site monoclonal antibody kits (developed by Cisbio) 
should be used [25, 134–137]
2The usage of antacid medications (e.g. proton pump inhibitors or histamine H2-receptor antagonists) increase the serum levels of CgA [138, 139]. Therefore, before 
measurement it is recommended to suspend these type of treatments, if possible, for at least seven days before the test, to avoid false-positive results [28]. Various 
diseases, including non-oncological gastrointestinal, cardiovascular, and renal conditions, and several tumour types, may also increase the serum levels [33, 140]
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WE-14 (the abbreviation comes from N- and C-
terminal amino acids and the length of the molecule) 
was isolated first from human metastatic hepatic cells 
originating from an ileal carcinoid tumour in 1992 [41], 
and also proved to be a CgA cleavage product. The pep-
tide was later isolated from human, bovine, and NOD 
mouse pancreatic beta cells, flask-shaped endocrine 
cells of intestinal crypts, and porcine adrenal chromaf-
fin cells [11, 42, 43].
In the late 1980s, it was reported that CgA has 
a cleavage product that can inhibit the nicotine-stimulat-
ed catecholamine secretion from cultured adrenal med-
ullary chromaffin cells, but all attempts to identify the 
active peptide failed until 1997 [44]. The cleaved CgA 
sections could inhibit significantly more catecholamines 
than the high molecular weight CgA. To identify the re-
sponsible domain within CgA, synthetic CgA-fragments 
were used to identify the exact cleavage site. The final 
20 amino acid-long CgA-fragment was named, after 
its function, as catestatin (CST). In vivo detection was 
reported a few years later [45].
Biological properties of chromogranin A
The human CgA gene (CHGA) spans 12 kilobases at 
q32.12 locus of chromosome 14 and contains eight exons 
[46–48]. The genes of vertebrate CgA and chromogranin B 
(CgB), a related member of the granin protein family, 
belong to two related monophyletic groups, which 
probably diverged from each other before ancestral fish. 
In all vertebrate species, CgA contains a large number 
of glutamic acid, aspartic acid, and hydrophilic proline 
residues (21%, 4% and 10% in humans), resulting in 
its acidic and hydrophilic properties [21, 49]. Several 
regions of CgA, being relatively conserved, exhibit simi-
larities to the calcium-binding domains of well-known 
calcium-binding proteins such as calmodulin or the 
vitamin D-dependent calcium-binding protein [50–52]. 
Two cysteine residues at the N-terminus, which together 
form a disulphide loop after posttranslational modifica-
tion, are a common structural characteristic of CgA and 
CgB in mammals [21, 53–56]. The WE-14 sequence is 
conserved during evolution, whereas PST and CST have 
no conserved homologous sequence in non-mammalian 
CgA proteins, indicating an ancient function of the for-
mer, and novel functions related to the latter [57]. These 
evolutionary patterns of different structural elements of 
CgA indicate that the intracellular sorting function re-
lated to acidic, hydrophilic, and calcium-binding abilities 
is more ancestral than the majority of the extracellular 
function related to cleavage products.
Foetal CgA production begins in humans between 
the 6th and 8th week of pregnancy in the chromaffin 
progenitor cells of the adrenal primordia and the 
gastrointestinal endocrine cells in stomach, proximal 
small intestine, distal colon, and rectum [58–61]. In 
adults, CgA is most abundantly produced by the chro-
maffin cells of adrenal medulla and the intrinsic neu-
rons of enteric nervous system in the gastrointestinal 
tract. The presence of CgA can also be detected in the 
gastrin-producing, the enterochromaffin, and the en-
terochromaffin-like cells of the stomach, and the gluca-
gon-producing alpha and insulin-producing beta cells 
of pancreatic islets. CgA-producing neurons reside in 
the central and other part of peripheral nervous systems 
such as the postganglionic neurons of the autonomic 
nervous system, the thyroid-stimulating, luteinising, 
follicle-stimulating, and growth hormone-producing 
endocrine cells of the anterior pituitary gland. The 
calcitonin-producing C-cells of the parathyroid glands 
also expressed CgA. Moreover, the neuroendocrine 
cells in lungs, spleen, prostate and thymus, atrial and 
ventricular cardiomyocytes, wound keratinocytes, the 
serous cells and ductal cells of salivary glands, germinal 
epithelial cells, and polymorphonuclear neutrophils 
also have CgA expression [23, 24, 49, 62–66].
Many extracellular signalling molecules can influ-
ence the expression of CgA. Both secretin and gastrin 
induce CgA transcription [67, 68], while oestradiol in-
hibits it in the pituitary gland [69, 70], and somatostatin 
diminishes the circadian rhythm of CgA in blood [71]. 
The receptors of gastrin and secretin are mainly ex-
pressed in the areas of the gastrointestinal tract and 
pancreas, but chromaffin cells are also responsive to 
secretin. Signal transduction pathways of protein 
kinases and extracellular signal-regulated kinases 
mediate gastrin and secretin extracellular signals via 
the cAMP response element in the CgA promoter 
[67, 68, 72, 73].
The CgA protein itself is synthesised in the rough 
endoplasmic reticulum and then transported to the 
Golgi apparatus. Inside the trans-Golgi network, CgA 
accumulates in the newly emerging secretory granules 
[74]. CgA has a high-capacity and low-affinity calcium 
binding function, which is primarily regulated by the 
more acidic pH levels inside the maturing secretory 
granules. The increasing H+- and Ca2+ ion concentra-
tions inside the granules can lead to conformational 
changes in the protein [75, 76]. Ca2+ can also enhance 
the capability of CgA to adhere to membrane [77]. Due 
to its calcium binding characteristics, after the binding 
of certain peptide hormones and neurotransmitters, 
CgA is able to selectively sort and pack these peptides 
into secretory granules [51, 78]. In Golgi cisterns pH is 
normally neutral, but the influx of H+ ions leads to an 
acidic pH; therefore, the acidic pH-shift induces the ag-
gregation of CgA and its bound peptides into secretory 
granules. Following the aggregation, the proteins are 
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locked inside the secretory granules when it detaches 
from the Golgi apparatus. Non-CgA-bounded peptides 
and proteins are not included in these granules [54, 
75, 79–81].
In parallel with protein and peptide sorting, the 
posttranslational modification of CgA include glyco-
sylation [82], phosphorylation [83], sulphation [84], 
carboxymethylation [85], pyroglutamylation [86], the 
formation of disulphide bonds, two-step proteolytic 
processing [87–89], and alpha-amidation [38, 90, 91], 
occurs intracellularly in trans-Golgi network and secre-
tory granules. Biologically active peptides with diverse 
functions are generated from CgA protein by the cleav-
age and the subsequent alpha-amidation (Figure 1, 
Table III). The in vivo isolated cleavage products of CgA 
in humans include vasostatin-1 and -2, PST, WE-14, 
cateslytin, and CST [25, 26, 81].
Proprotein convertases 1/3 and 2 (PC1/3 and PC2) are 
considered as the main enzymes performing the first 
step of proteolytic processing before secretion [87]. They 
are intracellular, Ca-activated serine endoproteases with 
acidic pH optima, and are ubiquitously expressed in 
endocrine and neuroendocrine cells, features that are 
logically suited to their localisation and function [92]. 
Besides CgA, other proproteins such as proinsulin, pro-
glucagon, and proopiomelanocortin are also processed 
by PC1/3 and PC2. Cathepsin L1 is a lysosomal cysteine 
endoprotease that mainly contributes to intracellular 
protein catabolism, but cathepsin L1 in vivo colocalises 
with CgA in the secretory granules of primary chromaf-
fin cells, and CgA can be a substrate for cathepsin L1 
both in vitro and in cella [88]. During the second step of 
the proteolytic process, carboxypeptidases E and/or D 
remove the C-terminal, basic amino acid residues after 
the proteolytic cleavage by PC1/3 and PC2, whereas 
Arg/Lys aminopeptidase is required to remove the 
N-terminal basic amino acid residues after the cleavage 
by cathepsin L1 [89]. After the proteolytic processing, 
the alpha-amidation of some CgA cleavage products 
(required for their full biological activity) is catalysed 
by peptidylglycine alpha-amidating monooxygenase, 
which is also localised in the trans-Golgi network and 
secretory granules of endocrine and neuroendocrine 
cells [93].
About 50% of CgA molecules are proteolytically 
processed in chromaffin cells before secretion [94], and 
the further extracellular cleavage of CgA may occur. 
Chromaffin cells express the components of the serine 
endoprotease plasmin system: thus plasmin is present 
in the local environment of the chromaffin cells, and 
extracellularly cleaves CgA to generate a bioactive 
product overlapping with CST [95, 96]. Furthermore, 
plasmin and the serine endoprotease thrombin can 
also cleave CgA in the bloodstream, in addition to 
their functions in blood coagulation pathway [97] 
(Figure 2).
Tissue- and cell-specific distribution of CgA cleav-
age products has been observed [98–100]. However, 
there is no information on the underlying differences 
in intra- and extracellular proteolytic processing. For 
instance, alpha and beta cells of pancreatic islets have 
a broad immunoreactivity to CgA region-specific 
antibodies, whereas somatostatin-producing delta 
and pancreatic polypeptide cells show a limited im-
munoreactivity [99].
The role of chromogranin A in type 1 
diabetes mellitus
Compared to wild type NOD mice, CgA-deficient 
knockout NOD mice (NOD.ChgA-/-) do not develop 
T1DM, or this is observed only in a very small portion 
of the population, suggesting CgA is a causative factor 
of T1DM; during the 12-month observation period 
T1DM appeared in more than 90% of the female wild-
type NOD mice, while only 3% of NOD.ChgA-/- female 
mice showed any symptoms of the disease. Male 
NOD.ChgA-/- mice had no signs of T1DM at all. Fol-
lowing the 12-month observation period, pathological 
examinations for insulitis, the inflammation of the 
pancreatic islets, was performed. Only 20% of the 
NOD.ChgA-/- mice had developed insulitis, while insu-
litis was present in all the wild-type NOD mice in both 
genders, and significantly lower amounts of CD4+ and 
CD8+ T-cells were found in the pancreatic tissues of 
NOD.ChgA-/- mice [101].
S S
Chromgranin A (CgA)
S S
Vasostatin-1
S S
Vasostatin-2 Catestatin (CTS)
Cateslytin
Pancreastatin
(PST)
WE-14
Figure 1. Proportionally scaled chromogranin A protein and its 
cleavage products isolated from human tissues. A disulphide bridge 
is located at the N-terminal (left) end of the protein. The exact size 
of cleavage products: vasostatin-1 — CgA1–76; vasostatin-2 — 
CgA1–115; pancreastatin (PST) — CgA250–301; WE-14 — CgA324–337; 
cateslytin — CgA344–358; catestatin (CST) — CgA352–372
Rycina 1. Proporcjonalnie skalowana proteina chromogranina 
A oraz produkty rozpadu izolowane z tkanek ludzkich. Mostek 
dwusiarczkowy znajduje się na N-końcowej (lewej) części białka. 
Dokładna wielkość produktów rozpadu: wazostatyna-1 — CgA1–76; 
wazostatyna -2 — CgA1–115; pankreastatyna (PST) — CgA250–301; 
WE-14 — CgA324–337; cateslytin — CgA344–358; katestatyna (CST) 
— CgA352–372
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Table III. Functions of the different chromogranin A (CgA) fragments
Tabela III. Funkcje różnych fragmentów chromograniny A (CgA)
CgA fragment Species from 
which it was 
isolated 
Name of the 
fragment
Function of the fragment Relation to the 
carbohydrate 
metabolism
T1
D
M
T2
D
M
GD
M
In
di
re
ct
 
co
nn
ec
tio
n
CgA1–76 Human Vasostatin 1 Anti-inflammatory effect [148, 149]
Antimicrobial effects [150]
Cardioprotective and anti-adrenergic effects [151]
Vascular permeability inhibition and
Endothelial cell proliferation of the blood vessels [152]
CgA1–115 Human Vasostatin 2
CgA1–128 Rat
Bovine
β-granin Inhibition of the parathyroid cell secretion in vitro [153]
CgA10–19 Human
Murine
— Diabetogenic CD8+ T-cell autoimmunity [102] X
CgA43–52 — X
CgA47–66 —
1 Chromofungin Potent antimicrobial effect through the activation of the 
polymorphonuclear neutrophils [154, 155]
CgA79–113 Bovine Vasoconstriction-
inhibiting factor 
(VIF)
Modulation of the vasoconstrictive effects of angiotensin II [156]
Counter-regulatory effect against hypertension [156]
CgA124–143 —
1 Chromostatin Inhibition of the secretion of chromaffin cells [157]
CgA173–194 Bovine Chromacin Inhibition of both Gram-negative and Gram-positive bacteria [158]
CgA250–301 Human
Murine
Porcine
Pancreastatin Inhibition of the glucose-stimulated and unstimulated insulin secretion 
[38, 39, 114, 119, 122]
Reduced hepatic glucose uptake [118, 120]
Decreased lipid synthesis and leptin secretion in adipocytes [117, 121]
Suppressed insulin signalling [114, 132, 159, 160]
Metabolic connection to dysglycaemia [161]
Higher serum levels in T2DM, GDM, obese hyperinsulinaemic, and obese 
glucose-intolerant hypertension patients [126, 128, 129]
X X X
CgA324–337 Human
Murine
WE-14 Diabetogenic CD4+ T-cell autoimmunity [11, 104–106] X
CgA344–358 Human
Bovine
Cateslytin Antibacterial activity: resistance against Staphylococcus aureus, [162], 
permeabilization of Escherichia coli’s cell wall [163]
A novel component of innate immunity [164]
The role of chromogranin A cleavage 
products in type 1 diabetes mellitus
Some of the newly-discovered autoantigens of T1DM 
are the cleavage products of CgA: WE-14 is known for 
its CD4+ T-cell autoreactivity [11], while other small, 
N-terminal CgA-fragments have CD8+-cell autoim-
munity [102].
CgA antigen-specific T cells are selected during the 
development of the thymus. CgA-specific mRNA is not 
detectable in embryonical medullary thymic epithelial 
cells, and this CgA-mRNA deficit may be the cause for 
the insufficient amount of CgA-reactive T-cell deletion 
because there is not enough CgA and/or WE-14 inside 
the thymus to mediate the deletion [11, 103]. When 
analysing the structure of the CD4+ autoreactive WE-14, 
it was found that despite its common antigen-binding 
motif, WE-14 is missing the N-terminal amino acids that 
usually bind easily to the NOD-mouse-specific MHC 
class II I-Ag7 p1 and p4 antigen-binding sites. These are 
usually necessary for a stable MHC class II binding. 
It can be assumed that the C-terminus of WE-14 can 
interact with the MHC class II I-Ag7 at a site outside 
of the normal peptide binding groove [11]. Outside 
→
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CgA fragment Species from 
which it was 
isolated 
Name of the 
fragment
Function of the fragment Relation to the 
carbohydrate 
metabolism
T1
DM
T2
DM
GD
M
In
di
re
ct
 
co
nn
ec
tio
n
CgA352–372 Human
Murine
Bovine
Catestatin Decreased plasma concentration in essential hypertension [165]
Counter-regulation of the β-adrenergic and endothelin-1 stimulated 
action [166] and antiadrenergic effect [167]
Normalisation of baroreflex [132]
Improved insulin sensitivity in catestatin-knockout mice [133]
Induction of angiogenesis [168]
Antimicrobial activity against bacteria, fungi, and yeasts [164]
Antioxidant activity [169]
Effective catecholamine release inhibition and endogenous nicotinic 
cholinergic antagonistic effect [113, 132]
Obesity-reducing effects [131]
X
CgA357–428 Porcine Parastatin Inhibition of the low Ca
2+-stimulated parathyroid secretion in vitro [170, 171]
CgA367–391 Bovine GE-25 No known biological effect so far [172, 173]
CgA417–442 Murine
Rat
Serpinin A novel, β-adrenergic-like cardiac modulator [174, 175]
1Synthetic peptides
Table III (cont.). Functions of the different chromogranin A (CgA) fragments
Tabela III (cd.). Funkcje różnych fragmentów chromograniny A (CgA)
of pancreatic β-cells in NOD mice, the CgA-induced 
CD4+ autoimmune reactions of other gastro-entero-
pancreatic tissues were not supported [42]. The observa-
tion that the CgA-induced autoimmune reaction is only 
detectable in the beta cells is still unclear to our present 
knowledge, although several theories have been pro-
posed [11]: 1. Selective autoimmune reactivity is caused 
by a difference in the proteolytic processing of CgA 
between beta cells and other cell types of pancreatic 
islets, or between islet cells and other cells with CgA 
expression; 2. WE-14 can only function as a pancreatic 
autoantigen after pancreas-specific post-translational 
modifications differing proteolytic processing [11].
The antigenic activity of WE-14 can be dramatically 
increased when modified by enzyme tissue transglu-
taminase (TGase) [104, 105] or with N-terminal amino 
acid additions [106]. TGase catalyses the glutamine 
deamidation of various proteins, changing glutamine 
to glutamic acid, and covalently crosslinking between 
the side chains of glutamine and lysine [107]. TGase 
converts WE-14 from a weak antigen into a potent 
one for CgA-reactive- and I-Ag7-restricted-CD4+ T cells 
[104]. The higher antigenicity of WE-14 is caused by the 
crosslinking, while the antigenic strength of deamidated 
WE-14 is similar to the unmodified molecule [34]. While 
healthy controls appear normal, newly diagnosed T1DM 
patients have shown elevated WE-14 antigenicity in 
their blood samples, which can be increased by in vitro 
TGase treatment. How often these modifications of 
WE-14 by TGase can occur in the pancreatic beta cells 
in vivo is currently unknown, but it was suggested that 
the increased immune response may develop due to 
aberrant post-translational modifications [105].
Different NOD mouse T-hybridoma cell lines carry-
ing different structural variants of T-cell receptors are 
responsive to low concentrations of a WE-14 that has 
been modified with an N-terminal arginine-leucine-
glycine-leucine addition (RLGL-WE14) in vitro. Reverse 
proteolysis or transpeptidation mechanisms may play 
a major role in the generation of RLGL-WE-14, which oc-
cur after the cleavage product is cleaved by the propro-
tein convertases from the original CgA molecule [106].
Human association studies [108–110] and a subse-
quent animal study with humanised NOD mice verified 
that the presence of human HLA-A*0201 serotype is an 
important contributor to the development of T1DM [110]. 
Samples from HLA-A*0201-positive transgenic NOD 
mice and onset HLA-A*0201-positive T1DM patients dia-
gnosed within one year showed CgA-fragment-related 
CD8+ T-cell autoimmunity [102]. Human CgA10–19, CgA43–52 
and murine mCgA10–19 and mCgA43–52 fragments that have 
been exposed to splenic CD8+ T-cell clones displayed 
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induced T-cell proliferation and increased cytotoxic activ-
ity. The same could not be observed in healthy controls 
nor in HLA-A*0201-negative T1DM patients.
Chromogranin A in type 2 diabetes 
mellitus
Both the salivary and serum levels of CgA were signifi-
cantly higher in T2DM patients than in healthy control 
subjects, and higher CgA concentrations were more 
frequently observed in the poorly controlled patients. 
Furthermore, a significantly higher number of various 
periodontal diseases occurred in both the well- and 
poorly-controlled diabetic groups with higher CgA 
levels [111]. Impaired salivary flow was correlated with 
significantly higher salivary and serum CgA levels. Two 
genetic variants of CHGA (rs9658635 and rs9658655) 
were associated with lower salivary flow and higher 
salivary CgA concentrations in T2DM [112].
CHGA knockout (CgA-KO) mice are obese on nor-
mal chow diet [113], have significantly higher glucose-
stimulated insulin secretion after glucose administration 
[114], have hypertension with higher catecholamine 
levels [113], and have insulin resistance in muscle cells 
[115]. Lower triglyceride levels have been found in CgA- 
-KO mice, despite similar amounts of fatty tissue [116].
The role of pancreastatin in the 
carbohydrate metabolism, in gestational 
and type 2 diabetes mellitus
PST is a negative regulator of insulin sensitivity and 
glucose homeostasis: Hyperglycaemia (a high glucose 
level in blood) can be at least partly promoted by the 
PST-mediated inhibition of insulin secretion. In addition, 
PST also increases blood glucose levels by reducing the 
hepatic glucose uptake through the inhibition of the 
insulin-stimulated glycogenesis in primary hepatocytes, 
2+Ca  influx through 
VGCCs triggers the 
exocytosis of 
secretory granules.
Gastrin or \
secretin
receptor
Extracellular signal molecules such 
as secretin & gastrin and other 
2+stimuli such as Ca
influx through VGGCs induce , 
PKA/PKC and the signal 
transduction pathway of ERK.
The cleavage products
 of CgA exert their autocrine 
and paracrine functions.
After exocytosis, CgA 
may be further cleaved by 
extracellular serine 
proteases.
The proteolytic processing of CgA and proproteins is 
performed by:
1. PC1/3, PC2 and carboxypeptidases E/D
2. Cathepsin L1 and Arg/Lys aminopeptidase.
CgA molecules aggregate at 
2+acidic pH and high Ca  
concentration in trans-Golgi 
cisterns. Proproteins are 
also sorted with aggregated 
CgA. The protelytic 
processing of CgA and 
proproteins starts.
The post-translational modification 
of CgA start in Golgi apparatus.Golgi 
apparatus
The translation 
of CgA occurs on RER.
ERK 
pathway
PKA/PKC
VGCCs
ERK pathways induces 
the transcription of CHGA 
via CREB/CRE.
CRE
CHGA
RER
Nucleus
Secretory 
granule
Protein
CgA
Figure 2. The gene expression, post-translational modification, secretion, and functions of chromogranin A. CgA — chromogranin 
A; CHGA — CgA gene; CRE — cAMP response element; CREB — cAMP response element-binding protein; ERK — extracellular 
signal–regulated kinase; PC1/3 and PC2 — proprotein convertases 1/3 and 2; PKA/PKC — protein kinase A and C; RER — rough 
endoplasmic reticulum; VGCCs — voltage-gated Ca2+ channels
Rycina 2. Ekspresja genu, modyfikacja potranslacyjna, wydzielanie i funkcje chromograniny A. CgA — chromogranina A; CHGA — 
gen CgA; CRE (cAMP response element) — element odpowiedzi na cAMP; CREB (cAMP response element-binding protein) — białko 
wiążące element odpowiedzi na cAMP; ERK (extracellular signal–regulated kinase) — kinaza regulowana zewnątrzkomórkowo; PC1/3 
and PC2 (proprotein convertases 1/3 and 2) — konwertazy proproteinowe 1/3 i 2; PKA/PKC (protein kinase A and C) — kinaza A i C; 
RER (rough endoplasmic reticulum) — retikulum endoplazmatyczne szorstkie; VGCCs (voltage-gated Ca2+ channels) — kanały 
wapniowe potencjałozależne
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decreasing the insulin-stimulated synthesis of lipids, and 
regulating the expression and secretion of leptin in adi-
pocytes [38, 39, 117, 118]. In hepatocytes and adipocytes, 
this is mediated by the G-protein activated phospholi-
pase C β3 isoforms (PLC-β3). PLC-β3 causes a cytosolic 
increase of intracellular Ca2+ ion concentration through 
inositol trisphosphate signalling, and the promotion of 
phosphokinase C (PKC) and mitogen-activated protein 
kinase pathways [119–122]. Several studies suggest that 
the insulin inhibition by PST in hepatocytes is also carried 
out through the activation of the nitric oxide (NO) path-
ways. NO has a known inhibitory function on insulin 
[123], while PST can increase NO production [114, 124].
The euglycemic state of the CgA-KO mice is 
maintained by the increased liver insulin sensitivity. 
Euglycaemia can be inhibited by the suppression of 
phosphoenolpyruvate carboxykinase (PEPC) and 
glucose-6-phosphatase (G6Pase) mRNAs, which leads 
to hypoglycaemia. Even in the absence of PEPC and 
G6Pase mRNAs, euglycaemia emerged with the ad-
ministration of external PST. In hepatocytes transfected 
with the G6Pase promoter fused with a luciferase re-
porter, the external PST induced an approximately 
six-fold transcriptional activation in a PKC- and NO 
synthetase-dependent manner, which ultimately sup-
presses insulin signalling [114].
PST influences the physiological homeostasis of blood 
glucose and insulin in humans. Fasting PST levels of 
T2DM patients have no significant difference compared 
to those of control subjects, but postprandial PST concen-
trations are significantly higher in T2DM patients during 
an oral glucose tolerance test (OGTT) [125]. The PST 
hypersecretion in pancreatic cells of T2DM patients may 
be due to the inhibition of the glucose-induced insulin 
secretion, ultimately resulting in hyperglycaemia [126]. 
PST levels of obese T2DM patients are significantly higher 
compared to those in non-diabetic obese patients and 
healthy control subjects. After a two-month supervised 
weight loss, PST concentrations did not change in these 
groups [127]. Like in T2DM patients, non-obese, essential 
hypertension patients with pre-diabetic symptoms (hy-
perinsulinemia or glucose-intolerance) had significantly 
increased postprandial PST levels during OGTT [128]. An 
increase (approximately one and a half-fold) in PST serum 
level was found in GDM patients, and a positive corre-
lation between different catecholamines (epinephrine, 
norepinephrine) and PST levels was also observed [129].
The presumed role of catestatin in 
carbohydrate metabolism
Concerning diabetes and carbohydrate metabolism, in 
the case of CST, only indirect correlations are available. 
Some authors assume that the peptide may contribute 
to the development of metabolic syndrome and diabetes 
mellitus. Its possible use as a future treatment for obesity 
and hypertension was also considered [130].
The bodyweight of obese CgA-KO mice [113] can 
be reduced to that of wild-type mice by administering 
external CST. The obesity-reducing effects are due to 
inhibition of alpha2-adrenergic receptor signalling and 
the enhancement of leptin receptor signalling [131].
CgA-KO mice have been shown to have hyperten-
sion, diminished baroreflex sensitivity, and increased 
catecholamine secretion. By external administration of 
CST, catecholamine levels and baroreceptor functions 
can be normalised to wild type values [132].
In the pathomechanism of the obesity-induced insu-
lin resistance and the consequential T2DM, the activation 
of hepatic Kupffer cells and monocyte-derived recruited 
macrophages have a crucial effect. CgA-KO mice were 
fed on a high-fat diet to create diet-induced obesity. Mice 
had elevated insulin and blood glucose levels, compared 
to wild type mice. External CST treatment normalised 
the glucose metabolism of hepatocytes and improved 
the insulin sensitivity of the mice by decreasing various 
circulating and hepatic lipid fractions, inflammatory 
cytokines, and via proinflammatory gene expression of 
hepatic Kupffer cells and macrophages. CST also had 
direct anti-inflammatory effects, decreasing macrophage 
activation and recruitment to the liver [133].
Conclusions
CgA is produced by various endocrine and neuroendo-
crine cell types of the different organs, where it plays an 
important role in the intracellular storage and selective 
secretion of various hormone peptides in the human 
body. During and after its secretion, it is cleaved, modi-
fied, and converted into biologically active extracellular 
peptide forms. The CgA cleavage products, such as 
WE-14, pancreastatin, and catestatin, all have significant 
and specific biological effects.
Recent studies suggest that the cleavage products 
of CgA contribute to the development of different 
diabetes mellitus forms. WE-14 fulfils a function as an 
autoantigen for both the diabetogenic, pancreatic beta 
cell-destroying CD4+ and CD8+ T cell populations in 
humans and in a NOD mouse model. CST and PST 
have regulator roles in T2DM and GDM.
Based on the impact of the currently available know-
ledge, and the wide range of functions of CgA-derived 
peptides, further studies are needed to investigate the 
possible treatment options and the relationships be-
tween diabetes mellitus, CgA, and its cleavage products.
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